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Hamster hearts transplanted into stable rat recipi-
ents of hamster livers (OLT rats) were hyperacutely 
rejected after transfer with unaltered rat antihamster 
hyperimmune serum (HS). This was followed by imme-
diate liver xenograft rejection in 4 of 6 rats. In con-
trast, simple heat inactivation of the rat HS resulted in 
prolonged survival of hamster hearts to 26 days with-
out deterioration effect in the liver xenografts. This 
effect was species-specific because third-party mouse 
heart grafts in OLT rats were hyperacutely rejected in 
minutes if either active or heat inactivated antimouse 
HS was given. In cytotoxicity experiments, the comple-
ment in OLT serum produced weak lysis of hamster 
lymphocytes, while efficiently doing so with mouse 
cell targets. Because normal hamster serum caused no 
lysis at all of hamster target cells, the residual low-
grade lysis of OLT serum was possibly being mediated 
by extrahepatic sources of rat C. In conclusion, the 
homology of C and target cells represents a mecha-
nism of protection that the liver confers to other or-
gans, and that is moat easily seen in xenografts but 
may be allospecifically operational with allografts as 
well within the limits of MHC restriction. 
We recently reported that a hamster liver xenograft trans-
planted into a rat fosters the acceptance of skin and heart 
from the same or third-party hamsters while not atfording 
protection to mouse organs from either humoral or cellular 
rejection Ill. However, this effect was species-specific rather 
than having the individual or donor-strain specificity that 
has been demonstrated by Kamada et a1. (2) in similar ex-
periments with rat liver allografts. The hamster-to-rat heart 
xenotransplantation model was appropriate for experimental 
inqUiries about complement because this organ is nonnally 
rejected in rats by mechanisms involving antibody and C 
actlVatlon 13, .J l. 
,\n explanation of the species-specific effect needs to ac-
commodate the facts that in vitro erythrocyte lysis by C pro-
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teins is homologous species-restricted (5), and that antibody-
coated target cells are resistant to lysis by homologous C but 
not by heterologous C (6). In addition, although in vitro cul-
ture studies have detected synthesis of C proteins by human 
and rodent mononuclear phagocytes (7, 8), the liver is the 
primary source of synthesis (9, 10). Finally, it has been es-
tablished that like the liver allograft (11, 12), the liver xe-
nograft retains its metabolic specificity, including the synthe-
sis of albumin, clotting factors, and C3 (13, 14). Thus we 
postulated that the conversion of recipient C to that of the 
donor after liver xenotransplantation could result in a more 
conducive C environment for target cells not only of the liver, 
but also of companion organs from the donor species that are 
transplanted simultaneously or later. 
To test this hypothesis, we transplanted hamster hearts 
into stable rat recipients of hamster xenografts and then 
perfonned serum transfer experiments with various hyper-
immune sera (HS)* as the source of antibody and of activated 
and inactivated C. Additional in vitro experiments were de-
signed to test the ability of the C in serum of stable liver 
xenograft recipients to support lysis of species-specific or 
third-party lymphocytes and of sheep red blood cells. 
:-.1ATERIALS AND METHODS 
Animals. Male Syrian /lolden hamsters 1100-120 g) and male 
Lewis ILEW) rats 12S0-270 g) purchased from Charles Rivers Labo-
ratories (Wilmington, MAl were used as donors and recipients re-
spectively. Male BIO.BR mice weighing 28-32 g were purchased from 
Jackson Laboratories IBar Harbor. MEl and used as third-party do-
nors. 
SurgIcal procedures. OrthotopIC liver transplantation was per-
formed accordmg to Kamada's cutTtechnique 115) with modifications 
i neluding cholecystectomy of the donor liver \ J 6), Heterotopic cardiac 
transplants were performed in the abdomInal cavity by the method of 
Ono and Lindsey Ilil. 
Rejection of the heart xenografts was defined by cessation of the 
heartbeat on abdomInal palpation and conlirmea by histology. Liver 
xenogratt rejection was suggested by the presence of signs of en-
cephalopathv followed bv death of the recIpIents. The diagnOSIS wa,; 
conlirmed bv histology . 
l'rotocoi o( immunosuppressIOn. lntrapentoneal injections were 
given of cVclophosphamide ICy-P) R mgtkgJday for 10 days. begun 
,imultaneouslv with 1 m!:/kgJday I.m. of FKS06. which was conttn-
ued for 30 days. No further treatment was given. In rats bearln!! 
hamster lIver xenogratts, test heart transplantation was periormed 
10-30 days after discontinuance of immunosuppression. 
'AbbreVlatlons. LVP, c\'c1ophosphamlde: HS. hypenmmune se' 
rum. 
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p,yporation of hyperimmune serum. Ten LEW rats received ham-
heart xenografts that were rejected in 3 days. Three days after 
d1iJ. the animals were exsanguinated for the serum collection. The 
_hamster Iymphocytotoxic titer was approximately 1:4096 with 
IlWe variation from animal to animal. The sera were divided into 
aJiquots of 1 ml and stored at -70°C until used 1--3 weeks later. In 
preparation for injection. the sera were thawed on ice (4°C) or 
&hawed and then warmed at 56°C for 30 min in order to inactivate 
\he complement. 
'Thn other LEW rats received a B10.BR mouse heart xenograft that 
.sa rejected in 2 days. On day 4, the animals were sacrificed and 
their sera collected as described above. The antimouse Iymphocyto-
toXic titer was 1:4096. 
For in vitro experiments, samples of the foregoing antihamster 
and antimouse HS. as well as sera from normal rats or rats bearing 
liver xenografts. were absorbed with hamster or B10.BR mouse 
apleen cells. This provided an antibody-free source of species-specific 
C. The absorption using 5x108 hamster or B10.BR spleen cells per 2 
m1 serum was carried out by incubation for 1 hr at 4°C. The absorbed 
sera were then collected by centrifugation. The entire procedure was 
done twice. Afterwards. cytotoxicity was undetectable by the C-de-
pendent cytotoxicity assay. 
In vivo expenmental design. The purpose of these experiments was 
to see If hyperacute rejection of hamster or mouse hearts was in-
duced by serum transfer of their specific antisera. In 30 experiments. 
hamster heart grafts were transplanted into LEW rats belonging to 
the following groups: (1) LEW rats that received no immunosuppres-
sion (n= 10): (2) LEW rats that were pretreated with the same 30-day 
protocol of immunosuppression used to induce liver xenograft accep-
tance but without liver transplantation In= 10); and (3) stable OLT 
recipients at 40-60 days after liver transplantation and 10 to 30 days 
after immunosuppression had been stopped (n = 10). 
At 10 min after revascularizing the heart xenograft. after it had a 
strong and regular beat. serum transfer was performed. Half the 
animals (n=5) in each of the 3 main groups were given 1 ml unal-
tered HS via the penile vein while the other half were given the same 
amount of inactivated serum (Table 1). AIl controls for groups 1 and 
3, unaltered (n=5) and inactivated normal rat serum was given. 
The same expenments were performed usmg BIO.BR mouse 
hearts lor transplantation to LEW reCIpient with injeCtion of active 
or heat·mactlvated rat antimouse HS (Table 2). After the serum 
transfer in both models. the time of rejection was recorded-iietined 
as the cessatIOn of heartbeat by direct observation or by daily pal-
pation. 
To determme ifthe injected antihamster antibodies in the HS used 
for group;) ammals were rapidly removed by the preVIOusly trans-
planted hamster liver. serial blood samples were analyzed in the rats 
of group;) before and every 5 min after the delayed heart xenotrans-
plantation l n = l). Antibodies were determined bv the CDC assay (see 
below). _. 
[n vitro studies. Two kinds of assays were performed, both de-
signed to test the efficacy and specificity of C in the serum of the rat 
recipient of a hamster liver xenograft compared with C in the serum 
of the unaltered or sensitized rat or other species (mouse, hamster. 
rabbit), All tested sera were rendered cytotoxic antibody-free by 
prior absorption with the prospective species target cells. 
CDC assay (hamster and mouse lymphocyte targets): These ex-
periments are tabulated in Table 3. To each of the antibody-free sera 
(the complement source), a constant amount was added of the same 
decomplemented antihamster or antimouse antibody used in the in 
vivo experiments (titer 1:4096). After washing in RPMI medium and 
isolation, the cells were resuspended at a concentration of 5X ll~/mlK 
Duplicate samples of 1 )ll of decomplemented HS (rat antihamster or 
rat antimouse) and 1 III of lymph node cell suspensions (hamster or 
BlO.BR mice) were placed into 72 well tissue-typing trays (Robbins 
Scientific, Sunnyvale, CAl. After incubation for 30 min at room tem-
perature, 2-fold dilutions of the different sources of C were added to 
each well with reincubation for another 30 min at 37°C under 95% 
°2, and 5% CO2, Then 5111 of 0.4% trypan blue was added to each well 
for staining. Dead cell percent was plotted against serum dilutions. 
The C titer was defined as the highest serum dilution with more than 
25% cell lysis. RPMI medium served as negative controls. 
Hemolytic assay (target SRBC): With this modification of Mayer's 
method (8). the etlicacy of SRBC-absorbed OLT serum was com-
pared with that of normal rat. rat antihamster. and normal hamster 
in lysing of sheep red blood cells after the addition of a known 
amount of antibody. The tested sera were prepared by absorption 
\\;th fixed SRBC for 15 min at 4°C. The constant antibody was rat 
antiserum to SRBC diluted 1:16. added to an equal volume of SRBC 
suspension (5X 106/mll in PBS + 0.01 M EDTA and followed by in-
cubation at 37°C for 30 min. The SRBC were washed three times 
with PBS + Ca 0.15 mM + Mg 0.5 mM EmBp~+lK Then 100 III of 
sensitized SRBC was distributed in a 96-well. U-bottomed Falcon 
plates <Becton Dickinson, Lincoln Park. NJ), and different amounts 
of C at the dilution of 1:2 were added. Additional amounts of mBp~+ 
were added to each well to reach a total amount of 200 Ill/well. The 
plates were incubated for 9 hr at 37°C. then centrifuged for 2 min at 
1000 rpm. Each well had a control with C but not SRBC to establish 
the background. The absorbance of the supernatant was evaluated at 
-iDS nm. 
Statistical anal.vses. Values were expressed as mean:!:SD. Stu· 
dent's t test was used to evaluate the differences observed between 
the mean values: differences were consldered to be significant at 
P<O.OS. 
RESULTS 
In Vivo experiments. Hamster hearts: Hamster hearts. 
which are normally rejected in 3 days. were hyperacutely 
rejected in a tew minutes if either unaltered or complement 
TABLE 1. SurvIval of hamster heart xenografts in liver xenograft reclplents injected with active or decomplemented rat antihamster hy· 
perimmune serum 
Heart reCIpients 
1 mmunosuppreSSlOn) 
1. :--iormal LEW a (nonel 
, LEW rat leVp 8 mg/kg/day 
. to.,. FK506 1 mg/kgtday x :30)" 
:; OLT rat" ICyP + FKS06) 
Active 
2.2.2,3.3 min 
'2.:.!.3.3.4 mm 
7.8.12.16.32 min 
Transterred hvpenmmune serum 
; MST!:SDJ Inncuve 
l2.4:!:O.5) 1l.1O.1S.1ii.32 mm 
l2.8:!:O.8) ti,12.12.:.!1.28 min 
115.1:!: 10.11 23.23.25.27.28 davs 
, LEW rat reCIpientS normally reject hamster hearts 10 a mean of 3.0 days Ill. 
. Pretreatment IThis kind of pretreatment normail.y extends sUrv1val of hamster hearts beyond 3 days I. 
1 MST:tSDl 
i 16.6:!:9.4) 
l.lS.8:!:8.6) 
!2S.2::2.2) 
LEW rats that receIved a hamster liver transplant 4~M days before and were Immunosuppressed with CyP and FK506 as 10 group 2 
for 30 davs. With no treatment thereafter. The preeXlstmg liver xenografts were not adverselv alfected at the time oi heart rejection usmg 
mactlvated HS. With active HS. the liver of 4 of 5 rats underwent humoral rejection In less than 24 hr. the lifth rat sUrv1ved another 50 days . 
. , When unaltered m=5) or decompiemented In=5) normal rat serum was given mstead of HS. heart xenograft sUrv1val was unaffected in 
group 1 (3 davs). and In group 3 (25 daYSI. 
--------------------
0-
. 
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TABLE 2. Survival of third party B10.BR mice heart xenografts in liver xenograft recipients injected with active or decomplemented 
rat antimouse hyperimmune serum 
Transferred hypenmmune serum 
Heart recipients (treatment) Active (MST:tSDl Inactive 
1. Normal LEW' (none) 
2. LEW rat (CyP B mglkglday x 10 + FK506 
2,2,3,3,3 min 
2,2,2,3,4 min 
(2.6±0.5) 5,5,11,19.23 min 
(2.6:t0.B) 6,9,15,21,30 min 
( 12.6:tB.1l 
(16.2:t9.6) 
1 mglkg/day x 30)b 
3. OLT rate (CyP + FK506) 2,3,3,B,10 min (5.2±3.5l 6,6,12,15,16 min (ll.0:t4.7) 
• LEW rat recipients normally reject B10.BR mice hearts in a mean of 2.7:t1.7 days (unpublished observation). 
b Pretreatment. _ _ 
C LEW rats that received a hamster liver transplant 40-60 days before and were immunosuppressed WIth CyP and FK506 as 111 group 2 
for 30 days, with no treatment thereafter. The liver xenografts were not adversely affected at the time of heart rejection. 
TABLE 3. Summary of in vitro cytotoxicity experiments 
comparing heterologous and homologous sources of C with 
that in OLT recipients 
Source of complement Lymphocyte target cell (lysis) 
( noncytotoxic) Hamster BIO.BR mice 
l. OLT recipient Weak Efficient 
2. Normal rat Efficient Efficient 
3. Rat antihamster HS Efficient ND 
4. Rat antimouse HS ND Efficient 
5. Normal hamster No lysis Modest 
6. Normal mouse ND No lysis 
7. Baby rabbit C· Efficient Efficient 
n Cederlane Laboratories Limited, Hornby, Onto All other sera 
were prepared in our laboratory. 
inactivated antihamster HS was given intraoperatively to 
untreated rats (group 1) or to rats pretreated with a 30-day 
course of immunosuppression (group 2) CTable 1). 
Hyperacute rejection of hamster hearts also occurred after 
their transplantation to the rat recipients of liver xenografts 
if the rat HS was unaltered. and in addition the liver was 
promptly rejected in 4 of 5 such experiments (group 3). Inac-
tivation of the rat HS prevented this humoral rejection of 
both organs (Table 1). 
In control experiments for groups 1 and 3. absorbed normal 
unaltered and decomplemented rat serum did not cause hy-
peracute rejection. showing that the alternative pathway of 
complement activation was not responsible for the HS effect 
(Table 1). 
In further controls for the group 3 experiments. serial an-
tibody titers in the rat recipients were measured before and 
every 5 min after heart xenotransplantation. These were es-
sentially the same for up to 60 min whether active or de-
complemented HS was administered (data not shown). ruling 
out differences of antibody absorption as an explanation for 
the drastically different reswts with and without HS comple-
ment. 
;-'Youse hearts: Mouse hearts underwent hyperacute rejec-
tion in untreated and previously immunosuppressed rats and 
in OLT recipients with the transfer of anti mouse HS whether 
or not the serum was C-inactivated. The rejections did not 
adversely affect the previously placed hamster liver xe-
nograft (Table 2). 
I n Vitro Experzments. Complement-dependent cytotoxicity 
(CDC): The serum complement from the rats bearing a ham-
ster liver caused only weak lysis of hamster lymphocytes. 
while etficientiy lysing mouse lymphocytes <Table 3). It was 
noteworthy that normal hamster serum caused no lysis at all 
of hamster target cells. These results and the control data 
outlined in Table 3 are shown in Figure 1. 
When the same OLT serum was used as a complement 
source for the mouse lymphocyte target (Table 3),lysis was at 
least as efficient as that caused by the serum or HS from rats, 
and serum from normal hamster or rabbit (Fig. 2). Mouse 
serum as a C source failed to cause lysis of mouse cells. This 
was analogous to the experiment in which hamster comple-
ment did not lyse hamster lymphocytes. Thus, in both experi-
ments, the benign nature of homologous C was evident ver-
sus the vigorous reactivity of heterologous C. 
Hemolytic assay: The hemolysis of SRBC caused by the 
OLT serum was equivalent to that produced by the serum of 
normal rats and greater than that of normal hamster serum. 
The most potent lysis was from rat HS (Fig. 3), a finding 
consistent with other research in non transplant models dem-
onstrating elevated C synthesis as part of the inflammatory 
response (19). 
DISCUSSION 
It is well known that the hepatocytes of a transplanted 
allograft (J2) or xenograft (13. 14) retain their metabolic 
specificity, and that much of the body's complement (perhaps 
all of some components) is produced by the liver (9. lUl. 
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FIGURE 2. BIO.BR mice lymphocyte lysis produced by OLT serum 
as a source of C in the presence of a known amount of decomple-
mented rat antimouse HS. Lysis caused by OLT serum (closed circle) 
was compared with that caused by baby rabbit C (open square), rat 
antimouse HS (closed triangle), normal rat serum (open circle), nor-
mal hamster serum (open triangle), and normal mouse serum (closed 
square). 
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one is donor. The evidence for both propositions is compelling 
from both the in vivo and in vitro experiments. In essence, 
the in vivo experiments showed how the systemic introduc-
tion of active C in hyperimmune antihamster rat serum into 
the rat recipient of a stably functioning hamster liver caused 
prompt humoral rejection of a secondarily engrafted hamster 
heart that otherwise would have been protected. Coinciden-
tally, the serum transfer caused prompt rejection of the liver 
itself. These lethal events were completely prevented by the 
simple expedient of decomplementing the serum by heating it 
at 56°C for 30 min. In experiments using rat antimouse se-
rum, third-party mouse hearts in the OLT recipients were 
hyperacutely rejected with or without complement inactiva-
tion of the antimouse antiserum with no harm to the hamster 
liver xenograft. 
This demonstration of the species specificity and efficacy of 
the dominant hamster complement system was confirmed by 
exhaustive in vitro assays, including complement dependent 
cytotoxicity. These tests also provided circumstantial evi-
dence of significant amounts of rat complement in the rat 
recipients of hamster livers. Normal hamster serum caused 
no lysis at all of target hamster cells. confirming the findings 
of Van den Bogaerde et al. (21), whereas serum from the OLT 
recipient was moderately lytic when used as the complement 
source. 
It remains to be studied in genetically controlled <inbred) 
models if the protection from humoral rejection endowed by 
the liver in the hamster to rat model is trans-species-specific 
without MHC restriction-or, more likely, if the generic um-
brella for all hamsters is merely a reflection of intensive 
inbreeding and minimal genetic diversity in this animal as 
we suggested previously ( 1). If MHC restriction is found, the 
xenograft model should provide much needed insight into the 
mechanisms of hyperacute allograft rejection in sensitized 
recipients and how these can be altered. A frequently re-
corded probable example of exploitation of MHC restriction 
in the context of our studies was tirst reported by Fung et a1. 
(22) and confirmed by others (23) who showed that a kidney 
ullograft could be successfully transplanted across a positive 
o 20 40 60 80 100 lymphocytotoxic crossmatch. us long as it was preceded by 
the liver 12 hr or more earlier from the same donor. 
Serum 1:2 (C) 1I.d] 
FIGURE 3. The hemolytic assay. C in OLT serum (open triangle) was 
tested in Its ability to lyse sensitized SRBC. Lysis was compared with 
that produced by rat antihamster HS (open square). normal rat 
serum (open circle), and normal hamster serum (closed circle). Re-
sults are the mean of 3 experiments .• P<O.Ol vs. normal rat serum. 
Notwithstanding the evidence that there is cumulatively sig-
nificant extrahepatic synthesis of C (7. 8). we postulated that 
the new supply of donor specltic C might be a survival ad-
vantage tor the transplanted liver as well as for other organs 
from the same donor that are exposed to the recipient's al-
tered metabolic enVlronment. It is now realized that chimenc 
donor cells that have migrated ubiquitously from the graft 
contribute to this changed environment (20) including the 
monocyte/macrophage lineage that synthesize complement 
(7.8). 
The experiments reported herein support the C protection 
hypothesis. and strongly suggest but do not prove that the 
xenograft recipient has :2 C systems of which the dominant 
The resistance to humoral rejection of the allograft liver 
itself can be explained by this mechanism. What must be 
accomplished for success with either a liver allograft or xe-
nograft (and to organs to which they extend protection) is 
survival and function of the new liver long enough to allow 
the complement transition to begin. This objective has been 
readily achieved in crossmatch-positive liver allograft recipi-
ents with a drug cocktail that Includes prostaglandin El and 
high doses of steroids (24 l. The soluble human complement 
receptor (type I) that inhibits the cleavage of complement 
components C, and C, und blocks the claSSical and alterna-
tive pathways of complement activation t:25-271. atfording 
":ignificant protection from humoral n'lectton (28. 29) might 
buy enough time when combined with conventional immuno-
suppressants to make this objective attainable with xe-
nografts. 
Another implication of these studies that could have pro-
found clinical significance IS appreciatIOn of the potential 
harm of infusing active human complement contained in the 
blood and blood products that are needed in large quantIties 
when human liver xenotransplantatlon is performed. With-
- -.. 
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out the precautions of complement inactivation, this could 
create conditions comparable to the in vivo animal experi-
ments of the present study. 
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